Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today introduced the IVIS Lumina XR in vivo imaging system, the latest addition to the IVIS product family. The Lumina XR system combines highly sensitive bioluminescence and fluorescence molecular optical imaging with the anatomical precision of digital x-ray. Integrating these three imaging modalities provides researchers with additional capabilities to explore the molecular basis of disease and determine the response to drug therapies.
Caliper's non-invasive IVIS preclinical molecular optical imaging technology is an innovative research tool that has greatly advanced both basic scientific research as well as the novel breakthrough research necessary to develop safe new drugs. To date, peer-reviewed publications show that IVIS technology has aided the discovery and development of five FDA-approved therapies and more than nine drug compounds in development. The introduction of the Lumina XR system takes this innovation one step further by combining optical fluorescent and bioluminescent images of biological activity with co-registered digital x-ray images, enhancing the anatomical context of the optical molecular signals. For example, with x-ray co-registration the researcher can view a detailed image of the skeleton, or even certain soft tissues, and can use those images as a reference point when using bioluminescence to more precisely locate a tumor or infection site in an animal.